Becton Dickinson and Co (BDX) Insider Thomas E. Polen, Jr. Sells 5,243 Shares
Becton Dickinson and Co (NYSE:BDX) insider Thomas E. Polen, Jr. sold 5,243 shares of the firm’s stock in a transaction dated Monday, November 19th. The stock was sold at an average price of $243.86, for a total transaction of $1,278,557.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
BDX stock opened at $243.40 on Tuesday. Becton Dickinson and Co has a 52-week low of $209.91 and a 52-week high of $265.87. The company has a market cap of $65.84 billion, a PE ratio of 22.43, a price-to-earnings-growth ratio of 1.69 and a beta of 1.19. The company has a quick ratio of 0.81, a current ratio of 1.23 and a debt-to-equity ratio of 0.95.
Becton Dickinson and (NYSE:BDX) last released its earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $2.93. The firm had revenue of $4.40 billion during the quarter, compared to analyst estimates of $4.36 billion. Becton Dickinson and had a net margin of 1.47% and a return on equity of 13.84%. The business’s revenue was up 39.0% on a year-over-year basis. During the same period last year, the business earned $2.40 earnings per share. Sell-side analysts predict that Becton Dickinson and Co will post 12.15 EPS for the current year.
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Ascension Asset Management LLC increased its position in shares of Becton Dickinson and by 4.2% during the second quarter. Ascension Asset Management LLC now owns 4,970 shares of the medical instruments supplier’s stock valued at $1,191,000 after acquiring an additional 200 shares in the last quarter. Bfsg LLC grew its position in Becton Dickinson and by 1.9% in the 2nd quarter. Bfsg LLC now owns 10,515 shares of the medical instruments supplier’s stock worth $2,519,000 after purchasing an additional 201 shares during the period. Toth Financial Advisory Corp grew its position in Becton Dickinson and by 0.8% in the 2nd quarter. Toth Financial Advisory Corp now owns 24,989 shares of the medical instruments supplier’s stock worth $5,986,000 after purchasing an additional 203 shares during the period. Northwestern Mutual Wealth Management Co. grew its position in Becton Dickinson and by 0.4% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 50,849 shares of the medical instruments supplier’s stock worth $12,181,000 after purchasing an additional 204 shares during the period. Finally, Tocqueville Asset Management L.P. grew its position in Becton Dickinson and by 1.0% in the 3rd quarter. Tocqueville Asset Management L.P. now owns 22,151 shares of the medical instruments supplier’s stock worth $5,782,000 after purchasing an additional 215 shares during the period. 86.25% of the stock is owned by institutional investors.
BDX has been the subject of several research analyst reports. KeyCorp raised their price objective on shares of Becton Dickinson and from $264.00 to $273.00 and gave the stock an “overweight” rating in a report on Thursday, November 8th. Wells Fargo & Co lifted their target price on shares of Becton Dickinson and from $275.00 to $290.00 and gave the company an “outperform” rating in a report on Thursday, September 6th. They noted that the move was a valuation call. Citigroup lowered their target price on shares of Becton Dickinson and from $289.00 to $279.00 and set a “buy” rating for the company in a report on Tuesday, November 13th. Barclays initiated coverage on shares of Becton Dickinson and in a report on Monday, October 15th. They set an “equal weight” rating and a $278.00 target price for the company. Finally, Morgan Stanley lifted their target price on shares of Becton Dickinson and from $250.00 to $280.00 and gave the company an “equal weight” rating in a report on Thursday, October 4th. Five research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $253.79.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
See Also: Buyback
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.